Commerzbank Aktiengesellschaft FI lowered its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 541,056 shares of the biopharmaceutical company’s stock after selling 8,501 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Bristol-Myers Squibb were worth $33,156,000 at the end of the most recent reporting period.
Several other large investors also recently added to or reduced their stakes in BMY. Vanguard Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Vanguard Group Inc. now owns 118,661,690 shares of the biopharmaceutical company’s stock valued at $6,611,829,000 after buying an additional 333,685 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after buying an additional 2,367,864 shares in the last quarter. Dodge & Cox boosted its stake in shares of Bristol-Myers Squibb by 1.6% in the second quarter. Dodge & Cox now owns 29,579,461 shares of the biopharmaceutical company’s stock valued at $1,648,168,000 after buying an additional 459,271 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after buying an additional 3,735,453 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Bristol-Myers Squibb by 3.9% in the second quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock valued at $1,339,612,000 after buying an additional 910,496 shares in the last quarter. 69.82% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $67.95 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $111,210.00, a price-to-earnings ratio of 28.79, a price-to-earnings-growth ratio of 2.07 and a beta of 1.08. Bristol-Myers Squibb Co has a 12-month low of $51.56 and a 12-month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. equities analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 annualized dividend and a dividend yield of 2.35%. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio is currently 67.80%.
In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at $37,031,717.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Theodore R. Samuels II acquired 4,000 shares of Bristol-Myers Squibb stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the transaction, the director now directly owns 22,000 shares of the company’s stock, valued at $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by corporate insiders.
A number of research firms recently weighed in on BMY. Citigroup set a $78.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, February 16th. Morgan Stanley upgraded Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $51.56 to $78.00 in a research note on Thursday, February 15th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. BMO Capital Markets set a $51.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday, February 14th. Finally, Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $66.18.
ILLEGAL ACTIVITY WARNING: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/24/commerzbank-aktiengesellschaft-fi-sells-8501-shares-of-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.